Skip to main content
SpringerLink
Log in

Amyloid imaging in Alzheimer’s disease: A literature review

  • Published:
The journal of nutrition, health & aging

Abstract

Therapies targeting amyloid-β peptide currently represent approximately 50% of drugs now being developed for Alzheimer’s disease. Some, including active and passive anti-Aβ immunotherapy, directly target the amyloid plaques. The new amyloid tracers are increasingly being included in the proposed updated diagnostic criteria, and may allow earlier diagnosis. Those targeting amyloid-β peptide allow identification of amyloid plaques in vivo. We need to gain insight into all aspects of their application. As florbetapir (Amyvid™) and flutemetamol (Vizamyl™) have received marketing authorization, clinicians require deeper knowledge to be rationally used in diagnosis. In this paper, we review both completed and ongoing observational, longitudinal and interventional studies of these tracers, our main objective being to show the performance of the four most commonly used tracers and their validation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):63–7.

    PubMed  Google Scholar 

  2. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013 May 7;80(19):1778–83.

    PubMed Central  PubMed  Google Scholar 

  3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19;297(5580):353–6.

    CAS  PubMed  Google Scholar 

  4. Hardy JA, Higgins GA (1992). Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992 Apr 10;256(5054):184–5.

    CAS  PubMed  Google Scholar 

  5. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004 Mar;55(3):306–19.

    CAS  PubMed  Google Scholar 

  6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the Nincds-Adrda Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984 Jul;34(7):939–44.

    CAS  PubMed  Google Scholar 

  7. Larson ME, Lesné SE. Soluble Aβ oligomer production and toxicity. J Neurochem. 2012 Jan;120 Suppl 1:125–39. doi: 10.1111/j.1471-4159.2011.07478.x. Epub 2011 Nov 28.

    Google Scholar 

  8. Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB (2010). Voxel-based analysis of Alzheimer’s disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage. 2010 Aug 15;52(2):488–96. Epub 2010 Apr 10.

    PubMed  Google Scholar 

  9. La Joie R, Perrotin A, Barré L, Hommet C, Mézenge F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, de la Sayette V, Eustache F, Desgranges B, Chételat G. Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (aβ) load in Alzheimer’s disease dementia. J Neurosci. 2012 Nov 14;32(46):16265–16273.

    PubMed  Google Scholar 

  10. Bourgeat P, Chételat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O; AIBL Research Group. β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology January 12, 2010 74:121–127.

    CAS  PubMed  Google Scholar 

  11. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM; AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011 Jan 19;305(3):275–83.

    CAS  PubMed  Google Scholar 

  12. Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, La Joie R, Tafani M, Hommet C, Chételat G, Mondon K, de la Sayette V, Cottier JP, Beaufils E, Ribeiro MJ, Gissot V, Vierron E, Vercouillie J, Vellas B, Eustache F, Guilloteau D. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):621–31. Epub 2012 Jan 18.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. J Neurosci. 2007 Oct 10;27(41):10957–68.

    CAS  PubMed  Google Scholar 

  14. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochondanguy H, Morandeau L, O’Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010 Aug;31(8):1275–83. Epub 2010 May 15.

    PubMed  Google Scholar 

  15. Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, Desanti S, Kemppainen N, Någren K, Kim BC, Tsui W, de Leon MJ. Regional analysis of FDG and PiB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2169–81. Epub 2008 Jun 20.

    PubMed Central  PubMed  Google Scholar 

  16. Ducharme S, Guiot MC, Nikelski J, Chertkow H. Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease? JAMa Neurol. 2013 Jul;70(7):912–4. doi: 10.1001/jamaneurol.2013.420.

    PubMed  Google Scholar 

  17. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Arora A, Saha K, Burns JD, Lowrey MJ, Mintun MA, Skovronsky DM; Florbetapir F 18 Study Investigators. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med. 2012 Mar;53(3):378–84. Epub 2012 Feb 13.

    CAS  PubMed  Google Scholar 

  18. Newberg AB, Arnold Se, Wintering N, Rovner BW, Alavi A. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med. 2012 Jun;53(6):902–7. Epub 2012 May 10.

    CAS  PubMed  Google Scholar 

  19. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, Mintun MA; Alzheimer’s Disease Neuroimaging Initiative. Amyloid-β imaging with Pittsburgh Compound B and Florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013 Jan;54(1):70–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011 May;10(5):424–35. Epub 2011 Apr 8.

    CAS  PubMed  Google Scholar 

  21. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, Tochondanguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008 Feb;7(2):129–35. Epub 2008 Jan 10.

    CAS  PubMed  Google Scholar 

  22. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010 Sep;68(3):319–29.

    PubMed  Google Scholar 

  23. Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and metaanalysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis. 2011;26(4):627–45.

    CAS  PubMed  Google Scholar 

  24. Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2003 Oct;2(10):605–13.

    CAS  PubMed  Google Scholar 

  25. Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, Krautkramer MJ, Kung HF, Skovronsky DM, Hefti F, Clark CM. Correlation of amyloid PET ligand florbetapir F 18 binding with aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012 Jan;26(1):8–16.

    CAS  PubMed Central  PubMed  Google Scholar 

  26. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, Hamilton RH, Sherwin P, Mclain R, Arnold SE. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011 Nov;68(11):1398–403. doi: 10.1001/archneurol.2011.153. Epub 2011 Jul 11.

    PubMed  Google Scholar 

  27. Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA, Ferrucci L, Pletnikova O, Mathis CA, Klunk WE, O’Brien RJ, Wong DF, Troncoso JC, Resnick SM. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol. 2011 Feb;68(2):232–40.

    PubMed Central  PubMed  Google Scholar 

  28. Ikonomovic MD, Klunk WE. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008 Jun;131(Pt 6):1630–45. Epub 2008 Mar 12.

    PubMed Central  PubMed  Google Scholar 

  29. Driscoll I, Troncoso JC, Rudow G, Sojkova J, Pletnikova O, Zhou Y, Kraut MA, Ferrucci L, Mathis CA, Klunk WE, O’Brien RJ, Davatzikos C, Wong DF, Resnick SM. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol. 2012 Dec;124(6):823–31. doi: 10.1007/s00401-012-1025-1. Epub 2012 Aug 5.

    PubMed Central  PubMed  Google Scholar 

  30. Hedden T, Van Dijk KR, Becker JA, Mehta A, Sperling RA, Johnson KA, Buckner RL. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009 Oct 7;29(40):12686–94.

    CAS  PubMed Central  PubMed  Google Scholar 

  31. Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012 Feb;69(2):223–9.

    PubMed Central  PubMed  Google Scholar 

  32. Riverol M, López OL. Biomarkers in Alzheimer’s disease. Front Neurol. 2011;2:46. Epub 2011 Jul 14.

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006 Aug 8;67(3):446–52.

    CAS  PubMed  Google Scholar 

  34. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain. 2007 Nov;130(Pt 11):2837–44. Epub 2007 Oct 10.

    PubMed  Google Scholar 

  35. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O’Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007 May 15;68(20):1718–25.

    CAS  PubMed  Google Scholar 

  36. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008 Nov;65(11):1509–17.

    PubMed Central  PubMed  Google Scholar 

  37. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer’s disease. Ann Neurol. 1999 Mar;45(3):358–68.

    CAS  PubMed  Google Scholar 

  38. Jack Cr Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010 Jan;9(1):119–28.

    CAS  PubMed Central  PubMed  Google Scholar 

  39. Berti V, Osorio RS, Mosconi L, Li Y, de Santi S, de Leon MJ. Early detection of Alzheimer’s disease with PET imaging. Neurodegener Dis. 2010;7(1–3):131–5. Epub 2010 Mar 3.

    CAS  PubMed Central  PubMed  Google Scholar 

  40. Fodero-tavoletti MT, Cappai R, Mclean CA, Pike KE, Adlard PA, Cowie T, Connor AR, Masters CL, Rowe CC, Villemagne VL. Amyloid imaging in Alzheimer’s disease and other dementias. Brain Imaging Behav. 2009 Sep;3(3):246–61. Epub 2009 Apr 7.

    PubMed  Google Scholar 

  41. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer’s Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain. 2009 May;132(Pt 5):1355–65. Epub 2009 Mar 31.

    PubMed Central  PubMed  Google Scholar 

  42. Hatashita S, Yamasaki H. Clinically different stages of Alzheimer’s disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis. 2010;21(3):995–1003.

    PubMed  Google Scholar 

  43. Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, Szoeke C, Ames D; AIBL research group. Alzheimers Dement. Addressing population aging and Alzheimer’s disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer’s Disease Neuroimaging Initiative. 2010 May;6(3):291–6.

    Google Scholar 

  44. Doré V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetélat G, Zhou L, Martins R, Ellis KA, Masters CL, Ames D, Salvado O, Rowe CC. Cross-sectional and longitudinal analysis of the relationship between aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMa Neurol. 2013 Jul;70(7):903–11. doi: 10.1001/jamaneurol.2013.1062.

    PubMed  Google Scholar 

  45. Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Brašic JR, Zhou Y, Raymont V, Kumar A, Ravert HT, Dannals RF, Pontecorvo MJ, Skovronsky DM, Lyketsos CG. Am J Geriatr Psychiatry. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. 2013 Mar;21(3):272–8. doi: 10.1016/j.jagp.2012.11.016.

    Google Scholar 

  46. Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF (2010). Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010 Mar 9;74(10):807–15. Epub 2010 Feb 10.

    CAS  PubMed Central  PubMed  Google Scholar 

  47. Chételat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of Ageing Research Group. Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer’s disease. Neurodegener Dis. 2012;10(1–4):141–4. Epub 2012 Feb 1.

    PubMed  Google Scholar 

  48. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ; Alzheimer’s disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009 May;132(Pt 5):1310–23. Epub 2008 Nov 28.

    CAS  PubMed Central  PubMed  Google Scholar 

  49. Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013 Apr 2;80(14):1341–8. doi: 10.1212/WNL.0b013e31828ab35d.

    CAS  PubMed Central  PubMed  Google Scholar 

  50. Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC. Cognition and beta-amyloid in preclinical Alzheimer’s disease: data from the AIBL study. Neuropsychologia. 2011 Jul;49(9):2384–90. Epub 2011 Apr 16.

    PubMed  Google Scholar 

  51. Rodrigue KM, Kennedy KM, Devous MD Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, Mathews D, Park DC. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012 Feb 7;78(6):387–95. Epub 2012 Feb 1.

    CAS  PubMed Central  PubMed  Google Scholar 

  52. Duff K, Foster Nl, Dennett K, Hammers DB, Zollinger LV, Christian PE, Butterfield RI, Beardmore BE, Wang AY, Morton KA, Hoffman JM. Amyloid Deposition and Cognition in Older Adults: The Effects of Premorbid Intellect. Arch Clin Neuropsychol. 2013 Jun 30.

    Google Scholar 

  53. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6820–5. Epub 2009 Apr 3.

    CAS  PubMed Central  PubMed  Google Scholar 

  54. Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, Protas H, Joshi AD, Sabbagh M, Sadowsky CH, Sperling RA, Clark CM, Mintun MA, Pontecorvo MJ, Coleman RE, Doraiswamy PM, Johnson KA, Carpenter AP, Skovronsky DM, Reiman EM. Apolipoprotein E e4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013 Jan;34(1):1–12. doi: 10.1016/j.neurobiolaging.2012.04.017. Epub 2012 May 24.

    CAS  PubMed  Google Scholar 

  55. Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Petersen RC, Jack CR Jr, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI). The role of apolipoprotein e (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci. 2013 Apr 1;5:11. doi: 10.3389/fnagi.2013.00011. eCollection 2013.

    Google Scholar 

  56. Ossenkoppele R, van der Flier WM, Zwan MD, Adriaanse SF, Boellaard R, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van Berckel BN. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology. 2013 Jan 22;80(4):359–65. doi: 10.1212/WNL.0b013e31827f0889. Epub 2012 Dec 19.

    CAS  PubMed  Google Scholar 

  57. Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, Murray J, Scheinin N, Någren K, Williams S, Glodzik L, de Santi S, Vallabhajosula S, de Leon MJ. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer’s. Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5949–54. Epub 2010 Mar 15.

    CAS  PubMed Central  PubMed  Google Scholar 

  58. Xiong C, Roe CM, Buckles V, Fagan A, Holtzman D, Balota D, Duchek J, Storandt M, Mintun M, Grant E, Snyder AZ, Head D, Benzinger TL, Mettenburg J, Csernansky J, Morris JC. Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch Neurol. 2011 Oct;68(10):1313–9.

    PubMed Central  PubMed  Google Scholar 

  59. Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O’Keefe G, Gong SJ, Gunawan RM, Saunder T, Ackerman U, Tochon-Danguy H, Churilov L, Phan TG, Rowe CC. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology. 2010 Feb 9;74(6):487–93.

    CAS  PubMed  Google Scholar 

  60. Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol. 2011 Jun;69(6):1032–42. doi: 10.1002/ana.22333. Epub 2011 Mar 17.

    CAS  PubMed Central  PubMed  Google Scholar 

  61. Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, Geda YE, Swenson-Dravis DM, Boeve BF, Senjem ML, Vemuri P, Petersen RC, Jack CR Jr. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 2012 Oct 9;79(15):1570–7. doi: 10.1212/WNL.0b013e31826e2696. Epub 2012 Sep 12.

    CAS  PubMed Central  PubMed  Google Scholar 

  62. Sojkova J, Zhou Y, An Y, Kraut MA, Ferrucci L, Wong DF, Resnick SM. Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol. 2011 May;68(5):644–9.

    PubMed Central  PubMed  Google Scholar 

  63. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL, Morris JC. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011 Nov;70(5):857–61. doi: 10.1002/ana.22608.

    CAS  PubMed Central  PubMed  Google Scholar 

  64. Chételat GI, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC; AIBI Research Group. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology. 2012 Feb 14;78(7):477–84. doi: 10.1212/WNL.0b013e318246d67a. Epub 2012 Feb 1.

    PubMed  Google Scholar 

  65. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009 Dec;66(12):1476–81.

    PubMed Central  PubMed  Google Scholar 

  66. Small GW, Siddarth P, Kepe V, Ercoli LM, Burggren AC, Bookheimer SY, Miller KJ, Kim J, Lavretsky H, Huang SC, Barrio JR. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol. 2012 Feb;69(2):215–22.

    PubMed Central  PubMed  Google Scholar 

  67. Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P; For the AIBI Research Group. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology. 2012 Oct 16;79(16):1645–1652.

    CAS  PubMed  Google Scholar 

  68. Kawas CH, Greenia DE, Bullain SS, Clark CM, Pontecorvo MJ, Joshi AD, Corrada MM. Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ Study. Alzheimers Dement. 2012 Nov 16. pii: S1552-5260(12)02380-1. doi: 0.1016/j.jalz.2012.06.005.

    Google Scholar 

  69. Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TL, Mintun MA, Holtzman DM, Morris JC. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013 May 7;80(19):1784–91. doi: 10.1212/WNL.0b013e3182918ca6. Epub 2013 Apr 10.

    CAS  PubMed Central  PubMed  Google Scholar 

  70. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O’Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assessment of aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011 Jan;69(1):181–92. doi: 10.1002/ana.22248.

    CAS  PubMed Central  PubMed  Google Scholar 

  71. Ossenkoppele R, van Berckel BN, Prins ND. Amyloid imaging in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2011 Sep 19;3(5):26.

    CAS  PubMed Central  PubMed  Google Scholar 

  72. Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, Viitanen M, Någren K, Helin S, Scheinin M, Rinne JO. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009 Oct 13;73(15):1186–92. Epub 2009 Sep 2.

    CAS  PubMed  Google Scholar 

  73. Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN. Longitudinal imaging of alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PEt. Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):990–1000. Epub 2012 Mar 23.

    CAS  PubMed  Google Scholar 

  74. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR Jr, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, Thompson PM; Alzheimer’s Disease Neuroimaging Initiative. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010 Aug;31(8):1284–303. doi: 10.1016/j.neurobiolaging.2010.05.003. Epub 2010 Jun 11.

    CAS  PubMed Central  PubMed  Google Scholar 

  75. Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer’s Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain. 2010 Nov;133(11):3336–48. Epub 2010 Oct 8.

    PubMed Central  PubMed  Google Scholar 

  76. Caroli A, Frisoni GB; Alzheimer’s Disease Neuroimaging Initiative. The dynamics of Alzheimer’s disease biomarkers in the Alzheimer’s Disease Neuroimaging Initiative cohort. Neurobiol Aging. 2010 Aug;31(8):1263–74. doi: 10.1016/j.neurobiolaging.2010.04.024. Epub 2010 Jun 11.

    CAS  PubMed Central  PubMed  Google Scholar 

  77. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH; Alzheimer’s Disease Neuroimaging Initiative. The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010 May;6(3):257–64.

    PubMed Central  PubMed  Google Scholar 

  78. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, Mcdade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012 Aug 30;367(9):795–804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11.

    CAS  PubMed Central  PubMed  Google Scholar 

  79. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL; Australianimaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013 Apr;12(4):357–67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8.

    CAS  PubMed  Google Scholar 

  80. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Lancet Neurol. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. 2013 Feb;12(2):207–16. doi: 10.1016/S1474-4422(12)70291-0.

    CAS  Google Scholar 

  81. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009 Dec;66(12):1469–75.

    PubMed Central  PubMed  Google Scholar 

  82. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, DeKosky ST. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009 May;65(5):557–68.

    PubMed Central  PubMed  Google Scholar 

  83. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010 Jan 19;74(3):201–9. Epub 2009 Dec 30.

    PubMed Central  PubMed  Google Scholar 

  84. Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Någren K, Helin S, Parkkola R, Viitanen M, Rinne JO. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011 Mar 22;76(12):1085–90. Epub 2011 Feb 16.

    CAS  PubMed  Google Scholar 

  85. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009 Sep 8;73(10):754–60. Epub 2009 Jul 8.

    CAS  PubMed Central  PubMed  Google Scholar 

  86. Sperling R, Salloway S, Raskind M, Ferris S, Honig L, Porsteinsson A, Sabbagh M, Fox N, Yuen E, Liu E, Lu Y, Lull J, Miloslavsky M, Wang D, Tudor C, Banerjee K, Nejadnik B, Guenzler V, Reichert M, Ketter N, Grundman M, Black R, Brashear R. Bapineuzumab Phase 3 trials in mild to moderate Alzheimer’s disease dementia in apolipoprotein E e4 carriers(Study 302) and non-carriers (Study 301), Safety and PIB PET amyloid imaging. Clinical Trials in Alzheimer’s Disease; 2012 Oct 29.

    Google Scholar 

  87. Hampel H, Lista S. Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging. 2013 Jan;17(1):54–63. doi: 10.1007/s12603-013-0003-1.

    CAS  PubMed  Google Scholar 

  88. Potter WZ. Dose ranging for trials through biomarkers of drug effects. J Nutr Health Aging. 2010 Apr;14(4):310–1.

    CAS  PubMed  Google Scholar 

  89. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012 Feb;8(1 Suppl):S1–68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2.

    Google Scholar 

  90. Gillette-Guyonnet S, Vellas B. The Toulouse Gérontopôle Research Center: report of activities, 2007–2011. J Alzheimers Dis. 2012;28(3):721–32. doi: 10.3233/Jad-2011-112202.

    PubMed  Google Scholar 

  91. Carrié I, van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, Dantoine T, Rouaud O, Bonnefoy M, Robert P, Cuffi MN, Bories L, Bordes S, Gasnier Y, Desclaux F, Sudres K, Pesce A, Vellas B. Recruitment strategies for preventive trials. The MAPT study (Multidomain Alzheimer Preventive Trial). J Nutr Health Aging. 2012 Apr;16(4):355–9.

    PubMed  Google Scholar 

  92. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 Aug;6(8):734–46.

    PubMed  Google Scholar 

  93. Dubois B, Picard G, Sarazin M. Early detection of Alzheimer’s disease: new diagnostic criteria. Dialogues Clin Neurosci. 2009;11(2):135–9.

    PubMed Central  PubMed  Google Scholar 

  94. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010 Nov;9(11):1118–27. Epub 2010 Oct 9.

    PubMed  Google Scholar 

  95. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May;7(3):280–92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.

    PubMed Central  PubMed  Google Scholar 

  96. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May;7(3):257–62. doi: 10.1016/j.jalz.2011.03.004. Epub 2011 Apr 21.

    PubMed Central  PubMed  Google Scholar 

  97. Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Boeve BF, Petersen RC. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012 May 15;78(20):1576–82. Epub 2012 May 2.

    CAS  PubMed Central  PubMed  Google Scholar 

  98. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May;7(3):270–9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.

    PubMed Central  PubMed  Google Scholar 

  99. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May;7(3):263–9. Epub 2011 Apr 21.

    PubMed Central  PubMed  Google Scholar 

  100. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM. Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. Alzheimers Dement. 2013 Jul;9(4):e106–9.

    PubMed  Google Scholar 

  101. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s association. J Nucl Med. 2013 Mar;54(3):476–90. doi: 10.2967/jnumed.113.120618.

    CAS  PubMed  Google Scholar 

  102. Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA; for the AV45-A17 Study Group. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2012 Nov 29.

    Google Scholar 

  103. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ; For the AV45-A11 Study Group. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology. 2012 Oct 16;79(16):1636–1644. Epub 2012 Jul 11.

    CAS  PubMed Central  PubMed  Google Scholar 

  104. Grimmer T, Wutz C, Drzezga A, Förster S, Förstl H, Ortner M, Perneczky R, Kurz A. The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment. Curr Alzheimer Res. 2012 Oct 3.

    Google Scholar 

  105. Nicolaas I. Bohnen David S.W. Djang, Karl Herholz, Yoshimi Anzai, Satoshi Minoshima. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J nucl Med January 1, 2012 vol. 53 no. 1 59–71.

    Google Scholar 

  106. The MICAD Research Team. N-Methyl-11C-2-(4’-methylaminophenyl)-6- hydroxybenzothiazole.

  107. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, Greenberg SM, Hyman BT, Growdon JH. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007 Mar;64(3):431–4.

    PubMed  Google Scholar 

  108. Herholz K, Ebmeier K. Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol. 2011 Jul;10(7):667–70.

    CAS  PubMed  Google Scholar 

  109. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004 Mar;55(3):306–19.

    CAS  PubMed  Google Scholar 

  110. Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, Lim N, Zhuang Z, Golding G, Choi SR, Benedum TE, Kennedy P, Hefti F, Carpenter AP, Kung HF, Skovronsky DM. Florbetapir f-18: a histopathologically validated Betaamyloid positron emission tomography imaging agent. Semin Nucl Med. 2011 Jul;41(4):300–4. doi: 10.1053/j.semnuclmed.2011.03.001.

    PubMed  Google Scholar 

  111. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasic JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010 Jun;51(6):913–20.

    CAS  PubMed Central  PubMed  Google Scholar 

  112. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009 Nov;50(11):1887–94. Epub 2009 Oct 16.

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi Ad, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011 Nov;68(11):1404–11. Epub 2011 Jul 11.

    PubMed  Google Scholar 

  114. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, Wai YY, Chang HP, Lo CW, Yao CH, Yen TC, Kung MP. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent—a pilot study. Nucl Med Biol. 2010 May;37(4):497–508. Epub 2010 Apr 7.

    CAS  PubMed  Google Scholar 

  115. Leung K. (e)-4-(2-(6-(2-(2-(2-([18F]-fluoroethoxy)ethoxy)ethoxy)pyridin-3- yl)vinyl)-N-methylbenzenamine. Molecular Imaging and Contrast Agent Database (MICAD)

  116. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011 May;10(5):424–35. Epub 2011 Apr 8.

    CAS  PubMed  Google Scholar 

  117. Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702–14. Epub 2011 May 6.

    CAS  PubMed  Google Scholar 

  118. Duara R, Loewenstein DA, Shen Q, Barker W, Potter E, Varon D, Heurlin K, Vandenberghe R, Buckley C. Amyloid positron emission tomography with (18)Fflutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement. 2012 Nov 22. pii: S1552-5260(12)00025-8. doi: 10.1016/j.jalz.2012.01.006.

    Google Scholar 

  119. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PIB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010 Apr;9(4):363–72. Epub 2010 Feb 26.

    CAS  PubMed  Google Scholar 

  120. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012 Feb;69(2):198–207. Epub 2011 Oct 10.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alzheimer’s disease center, Gerontopole, Purpan University Hospital, Toulouse, France

    Pascal Saidlitz, T. Voisin, B. Vellas & J. Delrieu

  2. Nuclear Imaging Department, Purpan University Hospital, Toulouse, France

    P. Payoux

  3. Inserm, UMR1027, Epidemiology and public health analyzes: Risks, chronic diseases and disabilities, Faculty of Medicine, Toulouse, F-31062, France

    T. Voisin & B. Vellas

  4. Inserm, UMR 825, Cerebral imaging and neurological handicaps, Toulouse University, Toulouse CEDEX 3, France

    P. Payoux

  5. Research and Memory Center from Montpellier, University Gui de Chauliac Hospital, Montpellier, France

    A. Gabelle

  6. Inserm, U1040, Biotherapy Institute, Montpellier, France

    A. Gabelle

  7. Department of Neurology, Service de Neurologie D, Hospices Civils de Lyon, Hôpital Neurologique, Lyon, France

    M. Formaglio

Authors
  1. Pascal Saidlitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Voisin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Vellas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Payoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Gabelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Formaglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Delrieu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pascal Saidlitz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saidlitz, P., Voisin, T., Vellas, B. et al. Amyloid imaging in Alzheimer’s disease: A literature review. J Nutr Health Aging 18, 723–740 (2014). https://doi.org/10.1007/s12603-014-0507-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12603-014-0507-3

Key words

Search

Navigation